Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated at Stifel Nicolaus

Investment analysts at Stifel Nicolaus initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report issued on Thursday, Benzinga reports. The brokerage set a “buy” rating and a $86.00 price target on the stock. Stifel Nicolaus’ price target suggests a potential upside of 309.91% from the stock’s previous close.

A number of other equities analysts have also weighed in on JSPR. Oppenheimer reiterated an “outperform” rating and issued a $80.00 price target on shares of Jasper Therapeutics in a report on Thursday, March 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th. Evercore ISI initiated coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price objective on the stock. Royal Bank of Canada began coverage on Jasper Therapeutics in a report on Thursday, March 28th. They set an “outperform” rating and a $70.00 target price for the company. Finally, TD Cowen started coverage on shares of Jasper Therapeutics in a report on Monday, March 18th. They issued an “outperform” rating on the stock. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics currently has an average rating of “Buy” and a consensus target price of $67.00.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR opened at $20.98 on Thursday. The company has a market cap of $315.96 million, a PE ratio of -3.73 and a beta of 2.24. The company has a 50-day simple moving average of $23.13 and a 200-day simple moving average of $19.18. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Tuesday, May 14th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.23. On average, analysts anticipate that Jasper Therapeutics will post -4.36 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Jasper Therapeutics in the first quarter worth $306,000. Ikarian Capital LLC acquired a new stake in shares of Jasper Therapeutics in the 1st quarter valued at about $3,088,000. StemPoint Capital LP bought a new stake in Jasper Therapeutics in the first quarter valued at about $3,794,000. Russell Investments Group Ltd. bought a new stake in shares of Jasper Therapeutics in the 1st quarter valued at approximately $2,343,000. Finally, Concurrent Investment Advisors LLC bought a new position in shares of Jasper Therapeutics in the 1st quarter worth about $599,000. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.